ATLAS PHARMA CONSULTING LIMITED

ATLAS PHARMA CONSULTING LIMITED

ATLAS PHARMA CONSULTING LIMITED - Company Information

Print Friendly Version

ATLAS PHARMA CONSULTING LIMITED

Company Registration Number:
12799003 (England and Wales)

Unaudited abridged accounts for the year ended 31 December 2022

Period of accounts

Start date: 01 January 2022

End date: 31 December 2022

ATLAS PHARMA CONSULTING LIMITED

Contents of the Financial Statements

for the Period Ended 31 December 2022

Balance sheet
Notes

ATLAS PHARMA CONSULTING LIMITED

Balance sheet

As at 31 December 2022


Notes
2022
17 months to 31 December 2021


£
£
Fixed assets
Tangible assets: 3 0 844
Total fixed assets: 0 844
Current assets
Debtors:   0 31,000
Cash at bank and in hand: 32,561 30,424
Total current assets: 32,561 61,424
Creditors: amounts falling due within one year:   (268,042) (356,652)
Net current assets (liabilities): (235,481) (295,228)
Total assets less current liabilities: (235,481) (294,384)
Total net assets (liabilities): (235,481) (294,384)
Capital and reserves
Called up share capital: 1,000 1,000
Profit and loss account: (236,481) (295,384)
Shareholders funds: (235,481) (294,384)

The notes form part of these financial statements

ATLAS PHARMA CONSULTING LIMITED

Balance sheet statements

For the year ending 31 December 2022 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 19 October 2023
and signed on behalf of the board by:

Name: D Zaret
Status: Director

The notes form part of these financial statements

ATLAS PHARMA CONSULTING LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2022

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

Turnover policy

Turnover represents amounts received or receivable in respect of goods and services supplied during the year, net of VAT and trade discounts

Tangible fixed assets and depreciation policy

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows:Land and buildings Leasehold: 5 years straight lineFixtures, fittings & equipment: 3 years straight line

ATLAS PHARMA CONSULTING LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2022

2. Employees

2022 17 months to 31 December 2021
Average number of employees during the period 0 1

ATLAS PHARMA CONSULTING LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2022

3. Tangible Assets

Total
Cost £
At 01 January 2022 1,215
Disposals (1,215)
At 31 December 2022 0
Depreciation
At 01 January 2022 371
Charge for year 405
On disposals (776)
At 31 December 2022 0
Net book value
At 31 December 2022 0
At 31 December 2021 844